SGLT2 inhibitors are recommended to reduce the risk of hospitalization for HF in patients with diabetes in the 2019 ESC/EASD guidelines for diabetes, pre-diabetes and CVD, and GLP-1 receptor agonists may be considered for the treatment of diabetes in patients with HF. The gene discussed is SLC5A2; the disease is hydrops fetalis.